HLA-A*03:01 (AA 25-305), (Tetramer) protein (His-Avi Tag,KRAS)

N° du produit ABIN7454302

Cette protéine Recombinant est produite dans HEK-293 Cells.

Aperçu rapide pour HLA-A*03:01 (AA 25-305), (Tetramer) protein (His-Avi Tag,KRAS) (ABIN7454302)

Antigène: HLA-A*03:01

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Détail du produit

Attributs du protein: AA 25-305, Tetramer

Purification/Conjugué: His-Avi Tag,KRAS

Fonction: Human HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein

Séquence: Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)and VVVGAGGVGK peptide

Specificité: Uni-Prot: NP_002107.3 (HLA-A*03:01), P61769 (B2M), VVVGAGGVGK

Attributs du produit: Recombinant Human KRAS WT(HLA-A*03:01) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: HLA-A*03:01

Sujet: Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.

Poids moléculaire: 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

NCBI Accession: NP_002107